AbbVie is diving headfirst into the weight reduction sector, securing rights to a hopeful medication from Gubra in an arrangement potentially hitting an astounding $2.2 billion. This demonstrates AbbVie’s dedication to contending in the progressively competitive obesity therapy arena.
TruBit Collaborates with Morpho to Introduce DeFi Unearned Revenue in Latin America
AbbVie Enters Weight Loss Sector with $2.2 Billion Deal
